According to new research at ACR Convergence 2023, the American College of Rheumatology's (ACR) annual meeting, continuing tumor necrosis factor inhibitors during pregnancy is not associated with ...
Kids with polyarticular-course juvenile idiopathic arthritis (JIA) who received a second tumor necrosis factor (TNF) inhibitor after failing one initially did just as well as those who changed to a ...
The FDA is requiring the manufacturers of tumor necrosis factor (TNF)-blockers to strengthen their existing warnings of opportunistic fungal infections in their prescribing information. While these ...
Treating inflammatory bowel disease (IBD) with tumor necrosis factor (TNF) inhibitors was paradoxically associated with an increased risk for other immune-mediated inflammatory diseases (IMIDs) in a ...
JERSEY CITY, N.J. & INCHEON, Korea--(BUSINESS WIRE)--Organon & Co. (NYSE: OGN) & Samsung Bioepis Co., Ltd. today announced that HADLIMA™ (adalimumab-bwwd), a biosimilar referencing Humira (adalimumab) ...
The FDA continues to receive reports of hepatosplenic T-Cell lymphoma (HSTCL) in adolescents and young adults treated for Crohn’s disease and ulcerative colitis with tumor necrosis factor (TNF) ...
FDA Issues Reminder on Risk for Serious Fungal Infections With TNF-alpha Blockers, Including Simponi
May 29, 2009 — The US Food and Drug Administration (FDA) has issued a reminder on the risk for serious fungal infections associated with all tumor necrosis factor-alpha (TNF-alpha) inhibitors, ...
INCHEON, Korea & JERSEY CITY, N.J.--(BUSINESS WIRE)--Samsung Bioepis Co., Ltd. and Organon & Co. (NYSE: OGN) today announced the U.S. Food and Drug Administration (FDA) has approved the citrate-free, ...
WASHINGTON (Reuters) - U.S. health regulators have received more reports of rare blood cancer in young patients taking a class of anti-inflammatory drugs used to treat digestive disorders. The drugs, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results